Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Overview
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Astex Pharmaceuticals Inc
BeyondBio Inc
ChoDang Pharm Co Ltd
MEI Pharma Inc
Neosome Life Sciences LLC
Rizen (Suzhou) Biosciences Co Ltd
Shanghai Haihe Biopharma Co Ltd
Tiziana Life Sciences Plc
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Drug Profiles
AT-7519 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BEY-1107 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD-650 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEOS-518 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zotiraciclib citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Dormant Products
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Discontinued Products
Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Product Development Milestones
Featured News & Press Releases
Oct 03, 2019: MEI pharma announces updated clinical data from voruciclib
Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Jun 03, 2019: Adastra Pharmaceuticals announces positive interim data from Phase 1b clinical trial of zotiraciclib in the treatment of recurrent malignant gliomas
May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
Apr 24, 2019: Tiziana reports encouraging interim clinical data from an ongoing phase 2a trial with milciclib in advanced liver cancer patients
Dec 03, 2018: Tiziana Completes patient enrollment in a phase 2a trial to evaluate tolerability and anti-tumor activity of Milciclib in hepatocellular carcinoma (HCC)
Dec 01, 2018: MEI Pharma presents preclinical data demonstrating Voruciclib synergistically induces apoptosis in combination with Venetoclax in acute myeloid leukemia cells at the 2018 American Society of Hematology Annual Meeting
Nov 01, 2018: MEI Pharma to present preclinical data of Voruciclib in combination with Venetoclax at ASH 2018
Oct 16, 2018: Tiziana Life Sciences presents data from animal studies demonstrating the potential synergistic activity of Milciclib with tyrosine kinase inhibitors to treat Hepatocellular Carcinoma (HCC) at the American Association for the Study of Liver Diseases (AASLD)
Jun 14, 2018: Lees Pharmaceutical Holdings: Update on An Investigational Oncology Product
May 16, 2018: Tiziana Life Sciences Announces Interim Analysis Data from an Ongoing Phase 2a Trial of Milciclib Safety and Tolerability in Sorafenib-refractory or -intolerable, Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients
Apr 09, 2018: Tiziana Life Sciences Announces a Poster Presentation on Phase II clinical data with Milciclib in Thymic carcinoma and Thymoma patients at the American Society of Clinical Oncology (ASCO) Meeting (June 1-5, Chicago IL)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adastra Pharmaceuticals Inc, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BeyondBio Inc, H2 2019
Pipeline by ChoDang Pharm Co Ltd, H2 2019
Pipeline by MEI Pharma Inc, H2 2019
Pipeline by Neosome Life Sciences LLC, H2 2019
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019
Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
【掲載企業】
Adastra Pharmaceuticals Inc
Astex Pharmaceuticals Inc
BeyondBio Inc
ChoDang Pharm Co Ltd
MEI Pharma Inc
Neosome Life Sciences LLC
Rizen (Suzhou) Biosciences Co Ltd
Shanghai Haihe Biopharma Co Ltd
Tiziana Life Sciences Plc
【免責事項】
https://www.marketreport.jp/reports-disclaimer